Helius Medical Technologies (HSDT) - Market Cap to Earnings
Helius Medical (HSDT) develops portable PoNS systems, where hardware sales are complemented by a high-margin SaaS therapy support service. The price action history with the -0.70 metric visualizes this transition. The biotech's success depends on insurance reimbursements and the test results of devices for post-stroke rehabilitation. Demand for non-invasive modulation is growing alongside the expansion of neurological center networks and regulatory approvals.
Analytical breakdowns for Helius Medical
- share price and expert price forecast:
- market capitalization indicators:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Capital Helius Medical|HSDT - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Helius Medical Technologies Inc.|HSDT - Company Total Debt|Debt to Net Assets Ratio Helius Medical Technologies, Inc.|HSDT - Company Long-Term Debt|Company Current Liabilities Helius Medical Technologies|Immediate Liquidity heliusmedical.com
- earnings and market ratios statistics:
HSDT - Net Profit|Net Profit Forecast Helius Medical|HSDT - P/E Multiple|Market Cap to Projected Earnings Helius Medical Technologies Inc.|HSDT - PEG Multiple|Enterprise Value to EBITDA Ratio Helius Medical Technologies, Inc.|HSDT - Operating profit EBITDA|Net earnings per share (EPS TTM) Helius Medical Technologies|HSDT - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months heliusmedical.com|HSDT - Earnings growth in current year|Expected earnings per share trend next year Helius Medical
General company analysis:heliusmedical.com - HSDT
Helius Medical (HSDT) maintains a monopoly position in the non-invasive therapy segment, allowing the company to embed a high premium into the cost of PoNS devices, which directly impacts the business's market valuation. By analyzing the company's P/E volatility, investors compare current market capitalization with net income to identify the gap between the asset's speculative price and its actual ability to generate earnings per share.
Analysis of competing companies
BIIB: Company Value to Net Income|P/E Multiple NBIX|RGC - Market Cap to Earnings|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|ACADIA Corp - Price to Earnings Ratio|Xenon Pharmaceuticals - P/E Multiple|Business Payback Period vikingtherapeutics.com VKTX|SUPN (Supernus) - Price to Earnings Ratio|Catalyst Pharma (CPRX) - P/E Multiple|Price to Earnings Ratio Denali Therapeutics Inc|Harmony Corp (HRMY) - Business Payback Period|Price to Earnings Ratio BHVN (Biohaven Ltd.)|AMLX (amylyx.com) - Company Value to Net Income|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|PRAX - Price to Earnings Ratio|Anavex Corp - P/E Multiple|Market Cap to Earnings CeriBell EEG|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon) - P/E Multiple|Omeros Corp. (OMER) - Business Payback Period|P/E Multiple NGNE|Price to Earnings Ratio AC Immune Inc ACIU|P/E Multiple VYGR (Voyager Therapeutics)|P/E Multiple neumoratx.com NMRA|SCLX - Price to Earnings Ratio|TVGN: Price to Earnings Ratio|ACOG: P/E Multiple|Cognition Therapeutics Inc. - Company Value to Net Income|Price to Earnings Ratio Inhibikase Therapeutics|cassavasciences.com (SAVA) - Business Payback Period|P/E Multiple ASRT|coyatherapeutics.com - Price to Earnings Multiple|Vistagen - Price to Earnings Ratio|Market Price to Net Income Ratio OVID (Ovid Therapeutics Inc)|ABOS - Price to Earnings Ratio|CRVO (cervomed.com) - Price to Earnings Multiple|ATHE: P/E Multiple|Market Cap to Earnings Clene (CLNN)|Price to Earnings Ratio PEPG|P/E Multiple Jupiter Neurosciences, Inc.|Price to Earnings Ratio Relmada Therapeutics (RLMD)|ANVS (annovisbio.com) - Company Value to Net Income|Price to Earnings Ratio Grace Therapeutics GRCE|Firefly Neuroscience, Inc. (AIFF) - Market Cap to Earnings|ANEW Medical, Inc. - P/E Multiple|Company Value to Net Income NRSN (NeuroSense Therapeutics)|RVPH: P/E Multiple|Market Cap to Earnings MetaVia (MTVA)|Price to Earnings Ratio NeurAxis|Price to Earnings Ratio PASG|P/E Multiple NEUP|Business Payback Period Minerva|Athira Pharma, Inc. - Price to Earnings Ratio|P/E Multiple addextherapeutics.com ADXN|ALZN - Price to Earnings Ratio|Business Payback Period Cyclerion Therapeutics CYCN|PTIX (protagenic.com) - Price to Earnings Ratio|Pasithea Therapeutics Corp. - Company Value to Net Income|Price to Earnings Ratio Cortigent Inc|Price to Earnings Ratio avenuetx.com (ATXI)|P/E Multiple BCLI|CARA - Market Cap to Earnings|P/E Multiple CHRO (Chromocell Therapeutics Corporation)|ELYM: Price to Earnings Multiple|Intra-Cellular - P/E Multiple|Business Payback Period longboardpharma.com LBPH|MRNS: P/E Multiple|Price to Earnings Ratio NKGen Biotech Inc|NRBO (NeuroBo) - P/E Multiple|P/E Multiple Sage Therapeutics Inc|Price to Earnings Ratio Synaptogenix, Inc. (SNPX)|Price to Earnings Ratio TRVN (trevena.com)|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|Company Value to Net Income WENA|CERE - Price to Earnings Ratio
